Clinical Trials Browser

Carcinoma, Hepatocellular

Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Biliary Tract Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms

Head and Neck Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

Lung Neoplasms, Multiple Pulmonary Nodules

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

Advanced Solid Tumor

Esophageal Squamous Cell Carcinoma

Locally Advanced and Metastatic Solid Tumors

Mid-low Rectal Cancer

Stomach Neoplasms

Head and Neck Neoplasms

Esophageal Squamous Cell Carcinoma

Stomach Neoplasms

Ovarian Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Uveal Melanoma

Uterine Cervical Neoplasms

Clinical Trials

Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

FRONT-1

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

HESTIA

A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

PPIO-004-EC001

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

A Benefit Population Atlas of nICT Versus nCT for LAGC

neoCHANCE-1

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

TALENT

BRIGHT

neoCHANCE-2

SITISVEAL

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer